CCAAT/enhancer binding protein β and its role in autoimmune diseases: a promising therapeutic target
Wang YY., Xu Y., Chen YL., Wei W., Chang Y.
Narrative Review on Neuroinflammation, Chronic Inflammation, Autoimmune Research, published in J Transl Med (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Transl Med (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41888827
- PMCID
- PMC13141571
- DOI
- 10.1186/s12967-026-08037-w
Abstract (original English)
BACKGROUND: The CCAAT/enhancer binding protein β (C/EBPβ) is a key transcription factor regulating immune homeostasis. Although its oncogenic roles are well-established, its context-dependent functions in autoimmune diseases, which affect 5–10% of the global population, remain incompletely understood. This review aims to synthesize current knowledge on C/EBPβ’s paradoxical roles in autoimmunity and evaluate its emerging therapeutic potential. MAIN BODY: We detail how C/EBPβ, through its antagonistic isoforms LAP*/LAP (activator) and LIP (repressor), operates as both a pathogenic driver and a protective regulator in a cell-type-specific manner across major autoimmune conditions. In rheumatoid arthritis, it coordinates synovitis, cartilage degradation, and bone erosion. In lupus nephritis, it promotes podocyte pyroptosis. In multiple sclerosis, it drives pathogenic Th17 differentiation and microglial activation. Conversely, in ulcerative colitis, it can also facilitate anti-inflammatory M2 macrophage polarization. Critically, we evaluate emerging strategies to target this transcription factor, including isoform-selective inhibitors and peptide-based degraders, which challenge its historical classification as “undruggable” and open novel therapeutic avenues. CONCLUSIONS: C/EBPβ emerges as a pivotal, context-dependent orchestrator of autoimmune pathogenesis. Understanding its isofo
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies.
Systematic Review on Neuroinflammation, published in Tissue Eng Regen Med (2026) — summary generated from the PubMed abstract.
- 2026
Tissue Eng Regen Med - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level ASystematic ReviewEurope PMC
Efficacy of Exosome-Based Therapies for Skin Rejuvenation: A Systematic Review of Human Studies
Systematic Review on Neuroinflammation, Skin Aging, published in Cureus (2026) — summary generated from the PubMed abstract.
- 2026
Cureus - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level ASystematic ReviewEurope PMC
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review
Systematic Review with a reported sample of 123 on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in Biologics (2026) — summary generated from the PubMed abstract.
- 2026
- n = 123
Biologics